JFLB(SZ:002762) Guan Cha Zhe Wang·2025-09-04 12:08Core Viewpoint - The stock price of Jinfa Labi has shown significant volatility despite a substantial increase in revenue, leading to confusion among industry experts regarding the company's financial health and future prospects [1][2][3]. Financial Performance - In the first half of 2025, Jinfa Labi achieved a revenue of 158 million yuan, representing a year-on-year growth of 101.99% [1]. - The revenue from maternal and infant products was 123 million yuan, accounting for 77.64% of total revenue, with a year-on-year increase of 62.34% [1]. - The medical beauty segment generated 33 million yuan, contributing to 21.03% of total revenue, with a year-on-year growth of 100% [1][2]. Cost and Profitability - The company's operating costs surged to 100 million yuan, a year-on-year increase of 183.11%, primarily due to the expansion of e-commerce channels and the consolidation of the medical beauty business [2]. - Sales expenses rose by 72.52% to 37.78 million yuan, while management expenses increased by 11.45% to 20.19 million yuan [2]. - Jinfa Labi reported a net loss attributable to shareholders of 17.92 million yuan, worsening from a loss of 2.75 million yuan in the same period of 2024 [2][5]. Market Dynamics - The stock price fluctuations are influenced by market sentiment and speculative trading, particularly in light of government policies promoting childbirth and the growth of the maternal and infant sectors [3]. - The integration of the medical beauty business is seen as a strategic move to create a dual growth engine alongside maternal and infant products, which has garnered market interest [3][5]. Company History and Challenges - Jinfa Labi, listed in June 2015, has faced a prolonged period of declining profits, with significant losses reported in recent years, raising concerns about its potential delisting [4]. - The company has seen a reduction in its store count from 1,133 in 2019 to 587 in 2024, indicating operational challenges [4].